Regulatory
HIGHTrigger: The quarter was impacted because customer approvals in Canada were delayed.
Monitor: regulatory
OneSource Specialty Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +65.2%Very WeakRe-Entry
In , OneSource Specialty Pharma Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +65.2% relative strength. Fundamentals: Very Weak.
OneSource Specialty Pharma Ltd Key Facts
- PE Ratio
- 688.0x
- Market Cap
- ₹21,039 Cr
- PAT Growth YoY
- -29%
- Revenue Growth YoY
- -26%
- OPM
- 6.0%
- RS vs Nifty 500
- +65.2%
Emerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
📊Debt increased 68% YoY — leverage rising
👔Promoter stake down 0.7% this quarter
🌐FII stake increased 1.9% this quarter
🏛️DII reducing — stake down 2.1%
Key Risks
1. Regulatory
HIGH2. Logistics
MEDIUMKey Numbers
PAT Growth YoY
-29%
Inflection Down
Revenue YoY
-26%
Inflection Down
Operating Margin
6.0%
-3000 bps YoY
PE Ratio
688.0
Current Price
₹1,835
Fundamental Score
15/100
Very Weak
3Y PAT CAGR
+51%
Market Cap
21.0K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for OneSource Specialty Pharma Ltd?
Earnings deceleration risks from management commentary
Logistics
MEDIUMTrigger: Management said constrained supply has to ease as more markets open and capacity is added.
Monitor: logistics
What Is OneSource Specialty Pharma Ltd's Management Saying?
Key quotes from recent conference calls
“This has since been deferred, as they had received certain requests for additional information from the regulatory agency. [Risk (regulatory): HIGH]”
“the supply chain overall continue to remain constrained, whether it is in API's or in cartridges or in devices. [Risk (logistics): MEDIUM]”
How Fast Is OneSource Specialty Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | -26% | +80% | Inflection Down |
| PAT (Net Profit) | -29% | +51% | Inflection Down |
| OPM | 6.0% | -3000 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: OneSource Specialty Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were OneSource Specialty Pharma Ltd's latest quarterly results?
OneSource Specialty Pharma Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -29.0% (inflecting downward)
- Revenue Growth YoY: -26.2%
- Operating Margin: 6.0% (volatile)
Is OneSource Specialty Pharma Ltd's profit growing or declining?
OneSource Specialty Pharma Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -29.0% (latest quarter)
- PAT Growth QoQ: -990.0% (sequential)
- 3-Year PAT CAGR: +51.1%
- Trend: Inflecting downward — consistent growth pattern
What is OneSource Specialty Pharma Ltd's revenue growth trend?
OneSource Specialty Pharma Ltd's revenue growth trend is inflecting downward.
- Revenue Growth YoY: -26.2%
- Revenue Growth QoQ: -22.9% (sequential)
- 3-Year Revenue CAGR: +80.0%
How is OneSource Specialty Pharma Ltd's operating margin trending?
OneSource Specialty Pharma Ltd's operating margin is volatile.
- Current OPM: 6.0%
- OPM Change YoY: -30.0% basis points
- OPM Change QoQ: -22.0% basis points
What is OneSource Specialty Pharma Ltd's 3-year profit and revenue CAGR?
OneSource Specialty Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +51.1%
- 3-Year Revenue CAGR: +80.0%
Is OneSource Specialty Pharma Ltd's growth accelerating or decelerating?
OneSource Specialty Pharma Ltd's earnings growth is inflecting downward with insufficient_data on a sequential basis.
- YoY Acceleration: -129.0% bps
- Margin Warning: Operating margins are under pressure
What is OneSource Specialty Pharma Ltd's trailing twelve month (TTM) performance?
OneSource Specialty Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹19 Cr
- TTM PAT Growth: +100.0% YoY
- TTM Revenue: ₹1,000 Cr
- TTM Revenue Growth: +29.9% YoY
- TTM Operating Margin: 27.8%
What is OneSource Specialty Pharma Ltd's current PE ratio?
OneSource Specialty Pharma Ltd's current PE ratio is 688.0x.
- Current PE: 688.0x
- Market Cap: 21.0K Cr
What is OneSource Specialty Pharma Ltd's price-to-book ratio?
OneSource Specialty Pharma Ltd's price-to-book ratio is 3.6x.
- Price-to-Book (P/B): 3.6x
- Book Value per Share: ₹515
- Current Price: ₹1835
Is OneSource Specialty Pharma Ltd a fundamentally strong company?
OneSource Specialty Pharma Ltd is rated Very Weak with a fundamental score of 15/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: -26.2% (10% weight)
- PAT Growth YoY: -29.0% (10% weight)
- PAT Growth QoQ: -990.0% (10% weight)
- Margins stable (10% weight)
Is OneSource Specialty Pharma Ltd debt free?
OneSource Specialty Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1,000 Cr
What is OneSource Specialty Pharma Ltd's return on equity (ROE) and ROCE?
OneSource Specialty Pharma Ltd's return ratios over recent years
- FY2023: ROCE -12.0%
- FY2024: ROCE -12.0%
- FY2025: ROCE 6.0%
Is OneSource Specialty Pharma Ltd's cash flow positive?
OneSource Specialty Pharma Ltd's operating cash flow is negative (FY2025).
- Cash from Operations (CFO): ₹-68 Cr
- Free Cash Flow (FCF): ₹-269 Cr
What is OneSource Specialty Pharma Ltd's dividend yield?
OneSource Specialty Pharma Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹1835
Who holds OneSource Specialty Pharma Ltd shares — promoters, FII, DII?
OneSource Specialty Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 30.5%
- FII (Foreign): 17.5%
- DII (Domestic): 20.6%
- Public: 31.4%
Is promoter holding increasing or decreasing in OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd's promoter holding has increased recently.
- Current Promoter Holding: 30.5% (Mar 2026)
- Previous Quarter: 29.9% (Dec 2025)
- Change: +0.55% (increasing — positive signal)
How long has OneSource Specialty Pharma Ltd been outperforming Nifty 500?
OneSource Specialty Pharma Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is OneSource Specialty Pharma Ltd a new momentum entry or an established outperformer?
OneSource Specialty Pharma Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the key risks in OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has 2 key risks worth monitoring
- [HIGH] Regulatory — The quarter was impacted because customer approvals in Canada were delayed.
- [MEDIUM] Logistics — Management said constrained supply has to ease as more markets open and capacity is added.
What did OneSource Specialty Pharma Ltd's management say in the latest earnings call?
In Q3 FY26, OneSource Specialty Pharma Ltd's management highlighted
- "This has since been deferred, as they had received certain requests for additional information from the regulatory agency. [Risk (regulatory): HIGH]"
- "the supply chain overall continue to remain constrained, whether it is in API's or in cartridges or in devices. [Risk (logistics): MEDIUM]"
Is OneSource Specialty Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why OneSource Specialty Pharma Ltd may be worth studying
- Currently showing mixed signals — monitor for clearer trend confirmation
What is the investment thesis for OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd investment thesis summary:
Risk Factors (Bear Case)
- Margins under pressure
- Key risk: Regulatory
What is the future outlook for OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: inflecting downward
- Margin Trend: volatile
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.